Contact

Pipeline

Nostopharma repurposes approved Hh inhibitors. In mouse models of non-hereditary HO, Hh blockade significantly reduced HO formation.

PIPELINE STRATEGY

Balanced portfolio, de-risked execution

Nostopharm prioritizes programs with clear biomarkers, scalable manufacturing, and partnership-ready commercialization paths.

Special thank you to:

Johnson & Johnson

Preclinical
NP104G
Therapeutic Area: Oncology

Advanced therapeutic candidate in preclinical development.

Proof of Concept
EctoBone Patch™
Therapeutic Area: Regenerative Medicine

Bone regeneration therapy in proof of concept stage.

Preclinical
NP102
Therapeutic Area: Immunology

Immunological therapeutic in preclinical evaluation.